$ASMB
Assembly Biosciences Inc

2016 Q3 Form 10-Q Financial Statement

#000114420416117669 Filed on August 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.850M $2.940M $2.490M
YoY Change 14.46% 18.07% 76.6%
% of Gross Profit
Research & Development $8.833M $7.519M $4.668M
YoY Change 90.77% 61.08% 326.03%
% of Gross Profit
Depreciation & Amortization $18.00K $18.00K $16.00K
YoY Change 0.0% 12.5% 1459.45%
% of Gross Profit
Operating Expenses $8.833M $7.519M $4.668M
YoY Change 90.77% 61.08% 326.03%
Operating Profit -$11.68M -$10.45M -$7.154M
YoY Change 63.98% 46.13% 185.45%
Interest Expense $100.0K $300.0K $210.0K
YoY Change -80.0% 42.86% 425.0%
% of Operating Profit
Other Income/Expense, Net $301.9K $211.2K
YoY Change 42.94%
Pretax Income -$11.57M -$10.15M -$6.940M
YoY Change 74.84% 46.29% 180.97%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$11.57M -$10.15M -$6.943M
YoY Change 74.89% 46.23% 181.16%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$671.5K -$589.1K -$405.4K
COMMON SHARES
Basic Shares Outstanding 17.23M shares 17.23M shares 17.18M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $58.60M $63.50M $70.70M
YoY Change -10.94% -10.18% 231.92%
Cash & Equivalents $23.79M $20.34M $53.52M
Short-Term Investments $34.90M $43.20M $17.20M
Other Short-Term Assets $600.0K $600.0K $605.2K
YoY Change -14.93% -0.85% 252.75%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $59.30M $64.10M $71.33M
YoY Change -10.83% -10.14% 228.0%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $100.0K $174.0K
YoY Change -36.1% -42.54% 2252.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $8.100M $11.40M $31.60M
YoY Change -74.2% -63.92%
Other Assets
YoY Change
Total Long-Term Assets $49.87M $53.10M $73.37M
YoY Change -31.82% -27.63% 991579.58%
TOTAL ASSETS
Total Short-Term Assets $59.30M $64.10M $71.33M
Total Long-Term Assets $49.87M $53.10M $73.37M
Total Assets $109.1M $117.2M $144.7M
YoY Change -21.88% -19.01% 565.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.800M $2.400M $1.300M
YoY Change 153.33% 84.62% -8.54%
Accrued Expenses $3.600M $2.600M $935.7K
YoY Change 203.23% 177.88% 1831.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.500M $5.000M $2.240M
YoY Change 182.85% 123.22% 49.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $11.60M $11.60M $11.60M
YoY Change 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.500M $5.000M $2.240M
Total Long-Term Liabilities $11.60M $11.60M $11.60M
Total Liabilities $19.10M $16.60M $13.84M
YoY Change 34.02% 19.94% 841.63%
SHAREHOLDERS EQUITY
Retained Earnings -$149.6M
YoY Change
Common Stock $17.19K
YoY Change 267.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $90.00M $100.6M $130.9M
YoY Change
Total Liabilities & Shareholders Equity $109.1M $117.2M $144.7M
YoY Change -21.88% -19.0% 565.13%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$11.57M -$10.15M -$6.943M
YoY Change 74.89% 46.23% 181.16%
Depreciation, Depletion And Amortization $18.00K $18.00K $16.00K
YoY Change 0.0% 12.5% 1459.45%
Cash From Operating Activities -$7.860M -$6.770M -$4.390M
YoY Change 51.74% 54.21% 89.22%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K $0.00 -$20.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $11.35M $6.710M -$48.78M
YoY Change -193.11% -113.76%
Cash From Investing Activities $11.32M $6.710M -$48.80M
YoY Change -192.86% -113.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 10.64M
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -7.860M -6.770M -4.390M
Cash From Investing Activities 11.32M 6.710M -48.80M
Cash From Financing Activities 0.000 0.000 10.64M
Net Change In Cash 3.460M -60.00K -42.55M
YoY Change -120.22% -99.86% 1734.05%
FREE CASH FLOW
Cash From Operating Activities -$7.860M -$6.770M -$4.390M
Capital Expenditures -$40.00K $0.00 -$20.00K
Free Cash Flow -$7.820M -$6.770M -$4.370M
YoY Change 50.97% 54.92% 88.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
43205005 USD
CY2015Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
40556652 USD
CY2016Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
11167421 USD
CY2015Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
23392129 USD
CY2016Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
53102934 USD
CY2015Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
65376032 USD
CY2016Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
11600000 USD
CY2015Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
11600000 USD
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-839362 USD
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-821585 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7519031 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4667754 USD
CY2016Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
10454130 USD
CY2015Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
7153905 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
48780784 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7951257 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-14357123 USD
us-gaap Net Income Loss
NetIncomeLoss
-14087624 USD
us-gaap Interest Income Other
InterestIncomeOther
935026 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15637607 USD
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
21731282 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
269499 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8502188 USD
us-gaap Interest Income Other
InterestIncomeOther
269499 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
590524 USD
us-gaap Net Income Loss
NetIncomeLoss
-21140758 USD
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14357123 USD
CY2015Q2 us-gaap Depreciation
Depreciation
16000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5854935 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.23
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.99
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14164451 shares
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21158535 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14221843 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6093675 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17225661 shares
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-344502 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2163 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47991 USD
us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
-17777 USD
us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
-134219 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
262956 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
114347 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7153905 USD
CY2016Q2 us-gaap Interest Income Other
InterestIncomeOther
444605 USD
CY2015Q2 us-gaap Interest Income Other
InterestIncomeOther
211234 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
301930 USD
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
211234 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-10152200 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-6942671 USD
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2486151 USD
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2935099 USD
asmb Accrued Offering Cost Related To Issuance Of Common Stock
AccruedOfferingCostRelatedToIssuanceOfCommonStock
0 USD
asmb Accrued Offering Cost Related To Issuance Of Common Stock
AccruedOfferingCostRelatedToIssuanceOfCommonStock
296825 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
17165332 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 USD
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17225660 shares
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17119488 shares
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10242067 USD
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7076890 USD
CY2016Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-142675 USD
CY2015Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
us-gaap Depreciation
Depreciation
37093 USD
us-gaap Depreciation
Depreciation
30397 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2977993 USD
us-gaap Share Based Compensation
ShareBasedCompensation
5206024 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15978100 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8056007 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
9211912 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-48828775 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
81311814 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6766188 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
24427032 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29091113 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53518145 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1050224 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
396694 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
591742 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
888459 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-147643 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
479878 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
81014989 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2977993 USD
us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
-17777 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4114861 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3233295 shares
CY2016Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
54372426 USD
CY2016Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
265119 USD
CY2016Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
151440 USD
CY2016Q2 us-gaap Depreciation
Depreciation
18000 USD
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1619978 USD
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1628975 USD
CY2016Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
0 USD
CY2015Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
106777 USD
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0 USD
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
182752 USD
CY2016Q2 asmb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
624554 USD
CY2015Q4 asmb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
120700 USD
CY2016Q2 asmb Future Stock Based Compensation Expense Remainder Of Fiscal Year
FutureStockBasedCompensationExpenseRemainderOfFiscalYear
1959807 USD
CY2016Q2 asmb Future Stock Based Compensation Expense Year Two
FutureStockBasedCompensationExpenseYearTwo
1959182 USD
CY2016Q2 asmb Future Stock Based Compensation Expense Year Three
FutureStockBasedCompensationExpenseYearThree
828835 USD
CY2016Q2 asmb Future Stock Based Compensation Expense Year Four
FutureStockBasedCompensationExpenseYearFour
271022 USD
CY2016Q2 asmb Futurestockbasedcompensationexpenseyearfive
Futurestockbasedcompensationexpenseyearfive
14095 USD
CY2016Q2 asmb Future Stock Based Compensation Expense Total
FutureStockBasedCompensationExpenseTotal
5032941 USD
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17225554 shares
CY2016Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5000000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y10M24D
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2977993 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5206024 USD
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1518138 USD
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2620244 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
10130 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
ASSEMBLY BIOSCIENCES, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001426800
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Trading Symbol
TradingSymbol
ASMB
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17225554 shares
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17225554 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17225662 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17225662 shares
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
13460 USD
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-10079 USD
asmb Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
0 USD
asmb Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
88 USD
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
0 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Use of Estimates</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Significant estimates inherent in the preparation of the accompanying financial statements include recoverability and useful lives (indefinite) of intangible assets, assessment of impairment of goodwill, and the fair value of stock options and warrants granted to employees, consultants, directors, investors, licensors, placement agents and underwriters.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company&#8217;s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company&#8217;s estimates and could cause actual results to differ from those estimates and assumptions.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
9282011 USD
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
34182760 USD
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
43464771 USD
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
53993 USD
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
832877 USD
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
886870 USD
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
64770366 USD
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
63948781 USD
CY2016Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
55211788 USD
CY2016Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
47508 USD
CY2016Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
232542 USD
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
134219 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
362279 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
134219 USD
CY2016Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
142675 USD
CY2015Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0 USD
asmb Operating Lease Expiration Month And Year
OperatingLeaseExpirationMonthAndYear
2016-08
CY2016Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
886870 USD
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
821585 USD
CY2016Q2 asmb Accured General And Administrative Expenses Current
AccuredGeneralAndAdministrativeExpensesCurrent
386414 USD
CY2015Q4 asmb Accured General And Administrative Expenses Current
AccuredGeneralAndAdministrativeExpensesCurrent
0 USD
CY2016Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
402637 USD
CY2015Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
138000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
755000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
297000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
344502 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0 USD
CY2016Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
16909 shares

Files In Submission

Name View Source Status
0001144204-16-117669-index-headers.html Edgar Link pending
0001144204-16-117669-index.html Edgar Link pending
0001144204-16-117669.txt Edgar Link pending
0001144204-16-117669-xbrl.zip Edgar Link pending
asmb-20160630.xml Edgar Link completed
asmb-20160630.xsd Edgar Link pending
asmb-20160630_cal.xml Edgar Link unprocessable
asmb-20160630_def.xml Edgar Link unprocessable
asmb-20160630_lab.xml Edgar Link unprocessable
asmb-20160630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v445440_10q.htm Edgar Link pending
v445440_ex31-1.htm Edgar Link pending
v445440_ex31-2.htm Edgar Link pending
v445440_ex32-1.htm Edgar Link pending
v445440_ex32-2.htm Edgar Link pending